FDA Approves Ropeginterferon Alfa-2b-NJFT for Polycythemia Vera

On November 12, 2021, the U.S. Food and Drug Administration (FDA) approved ropeginterferon alfa-2b-njft for the treatment of adults with polycythemia vera.

Read the FDA announcement.

Read PharmaEssentia's announcement for more information.

Posted 11/15/2021